Posted by Michael Wonder on 10 Jan 2020
ICER releases evidence report on acute treatments for migraine
10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among them; generic triptans remain the most effective option for acute treatment for most patients requiring prescription medications.
The Institute for Clinical and Economic Review today released an evidence report assessing the comparative clinical effectiveness and economic value of three acute treatments for migraine: lasmiditan (Reyvow, Eli Lilly), rimegepant (Biohaven), and ubrogepant (Ubrelvy, Allergan).
This Evidence Report will be reviewed at an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council in Chicago, IL on 23 January 2020.
